RxDoctor Payments DataLook up a doctor →

Max Kim, MD

Glaucoma Specialist · Phoenix, AZNPI 1851300461

Payments from drug & device makers

$485,531in general payments, 2019–2025

Across 445 payments — averaging $1091.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Aerie Pharmaceuticals, Inc.$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Alcon$1K
  • Glaukos Corporation$801
  • plus $3K from 19 others

What the payments were for

  • Travel & lodging$1,39013%
  • Food & beverage$8,81985%
  • Education$871%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$621,204
Medicare patients
1,259
Services billed
7,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost452$253,623
RhopressaNetarsudil Mesylate257$107,207
Alphagan PBrimonidine Tartrate164$70,739
CombiganBrimonidine Tartrate/Timolol85$48,363
RocklatanNetarsudil Mesylat/Latanoprost103$43,121
VyzultaLatanoprostene Bunod66$28,907
SimbrinzaBrinzolamide/Brimonidine Tart95$24,175
RestasisCyclosporine25$21,507
Travoprost109$17,694
Brinzolamide62$15,737
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat931$14,915
AzoptBrinzolamide20$13,732
Latanoprost1,149$12,797
CequaCyclosporine13$12,548
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$8,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$476,541$394,232726 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$1,221$150,328360 claims
AlconSimbrinza, Azopt$1,154$37,907115 claims
Bausch & Lomb Americas Inc.Vyzulta$292$28,90766 claims
Sun Pharmaceutical Industries Inc.Cequa$1,192$12,54813 claims
NovartisTravatan Z$168$6,07613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →